MedTrace Logo

Lucentis for Central Retinal Vein Occlusion (CRVO)

NCT00406796 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2013-12-12

No results posted yet for this study

Summary

The purpose of this study is to determine whether ranibizumab will be effective in reducing if not eliminating the macular edema associated with the disease, central retinal vein occlusion (CRVO).

Conditions

  • Central Retinal Vein Occlusion

Interventions

DRUG

Ranibizumab

0.3mg and 0.5mg dose of Ranibizumab 0.05ml administered intravitreally

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • California Retina Consultants

    lead OTHER

Principal Investigators

  • Dante J Pieramici, M.D. · California Retina Consultants

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2008-09-30
Completion
2010-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00406796 on ClinicalTrials.gov